| Heading: |
Medicines and Healthcare Products Regulatory Agency: Fees and Charges |
| Question ID: |
1744095 |
| UIN: |
15739 |
| House: |
Commons |
| Date tabled: |
2024-11-25 |
| Asking Member ID: |
4131 |
| Asking Member display name: |
Jim Shannon
|
| Asking Member handle: |
jimshannonmp
|
| Asking Member Twitter reference: |
@jimshannonmp
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the proposed reform of Medicines and Healthcare products Regulatory Agency statutory fees on investment in the UK market by medical technolo |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components for transfusion in the United Kingdom.Most of the MHRA’s income comes from charging fees for its services. Its fees are set to recove... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |